FDA to quickly review Incyte’s Jakafi in chronic GVHDThe FDA is to begin a fast review of Incyte’s Jakafi (ruxolitinib) for patients with chronic graft-versus-host disease Share XFDA to quickly review Incyte’s Jakafi in chronic GVHDhttps://pharmaphorum.com/news/fda-to-quickly-review-incytes-jakafi-in-chronic-gvhd/
Incyte makes bid to join the checkpoint inhibitor clubIncyte has filed its PD-1 inhibitor retifanlimab with the FDA, seeking approval to treat a form of anal Share XIncyte makes bid to join the checkpoint inhibitor clubhttps://pharmaphorum.com/news/incyte-makes-bid-to-join-the-checkpoint-inhibitor-club/
Novartis/Incyte draw blank with Jakafi in COVID-19Novartis/Incyte’s Jakafi (ruxolitinib) looks unlikely to be added to the list of therapies that can be used against Share XNovartis/Incyte draw blank with Jakafi in COVID-19https://pharmaphorum.com/news/novartis-incyte-draw-blank-with-jakafi-in-covid-19/
Incyte/Morphosys take on CAR-Ts with $198,000 per year antibodyIncyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope Share XIncyte/Morphosys take on CAR-Ts with $198,000 per year antibodyhttps://pharmaphorum.com/news/incyte-morphosys-take-on-car-ts-as-lymphoma-antibody-monjuvi-approved-in-us/
Novartis takes $485m hit after axing eczema drug from pipelineNovartis has axed development of its mid-stage eczema drug ZPL389, taking a $485 million hit in the process. Share XNovartis takes $485m hit after axing eczema drug from pipelinehttps://pharmaphorum.com/news/novartis-takes-485m-hit-after-axing-eczema-drug-from-pipeline/
FDA approves Incyte’s Pemazyre for rare bile duct cancerThe FDA has approved Incyte’s Pemazyre (pemigatinib), the first targeted treatment for a rare cancer of the bile Share XFDA approves Incyte’s Pemazyre for rare bile duct cancerhttps://pharmaphorum.com/news/fda-approves-incytes-pemazyre-for-rare-bile-duct-cancer/
FDA to quickly review Novartis’ capmatinib in rare lung cancerThe FDA has agreed to fast-track its regulatory review of Novartis’ capmatinib in a hard-to-treat form of lung Share XFDA to quickly review Novartis’ capmatinib in rare lung cancerhttps://pharmaphorum.com/news/fda-to-quickly-review-novartis-capmatinib-in-rare-lung-cancer/
Incyte gets much-needed boost as eczema cream trial hits targetUS biotech Incyte has announced positive topline results from a phase 3 trial of its ruxolitinib eczema cream Share XIncyte gets much-needed boost as eczema cream trial hits targethttps://pharmaphorum.com/news/incyte-gets-much-needed-boost-as-eczema-cream-trial-hits-target/
MorphoSys gets $750m from Incyte for anti-CD19 cancer drugIncyte has agreed a deal with Germany’s MorphoSys to license an antibody that could be an alternative to Share XMorphoSys gets $750m from Incyte for anti-CD19 cancer drughttps://pharmaphorum.com/news/morphosys-gets-750m-from-incyte-for-anti-cd19-cancer-drug/
